StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB – Free Report) in a research report report published on Friday morning. The brokerage issued a sell rating on the stock.
Trinity Biotech Price Performance
Trinity Biotech stock opened at $0.69 on Friday. The firm has a market cap of $12.37 million, a price-to-earnings ratio of -0.30 and a beta of 1.20. Trinity Biotech has a fifty-two week low of $0.63 and a fifty-two week high of $3.55. The firm has a fifty day moving average price of $0.81 and a two-hundred day moving average price of $1.17.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC boosted its position in shares of Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 5.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 378,590 shares of the company’s stock after acquiring an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 at the end of the most recent quarter. 78.97% of the stock is owned by hedge funds and other institutional investors.
Trinity Biotech Company Profile
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Further Reading
- Five stocks we like better than Trinity Biotech
- Canada Bond Market Holiday: How to Invest and Trade
- How to Build the Ultimate Everything ETF Portfolio
- How to Short Nasdaq: An Easy-to-Follow Guide
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
